| Dirk Bradley Bahoravitch, MSN, CRNA | |
|
1067 N 500 W, Provo, UT 84604-3305 | |
| (801) 374-0354 | |
| Not Available |
| Full Name | Dirk Bradley Bahoravitch |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 1067 N 500 W, Provo, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184083826 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 53485 (Idaho) | Primary |
| Entity Name | Radius Anesthesia Of New Mexico Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376092403 PECOS PAC ID: 1153672159 Enrollment ID: O20181001000769 |
News Archive
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.
The now classic lab manual Antibodies, by Harlow and Lane, has been revised, extended, and updated by Edward Greenfield of the Dana-Farber Cancer Center, with contributions from other leaders in the field.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
The Dallas Morning News reports on the lure of the medical imaging business, which is many say is a "growth industry," including the idea that a "second- or third-hand MRI machine" can be purchased by a physician practice or free-standing imaging center for a few hundred thousand dollars but yield millions in new revenue. A report by America's Health Insurance Plans says as many as half the scans are unnecessary, and a McKinsey Global Institute study found the extra machines produce around $26.4 billion in additional costs each year. In addition, they expose patients to avoidable radiation (McNeill, 9/22).
Citing "serious and irreversible harm to teens," the American Civil Liberties Union asked an Illinois court to strike down a newly effective law that prevents teens from having an abortion unless they notify a parent or go to court.
› Verified 3 days ago
| Entity Name | Main Street Anesthesia Of New Mexico, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275010985 PECOS PAC ID: 3476807538 Enrollment ID: O20181108002622 |
News Archive
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.
The now classic lab manual Antibodies, by Harlow and Lane, has been revised, extended, and updated by Edward Greenfield of the Dana-Farber Cancer Center, with contributions from other leaders in the field.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
The Dallas Morning News reports on the lure of the medical imaging business, which is many say is a "growth industry," including the idea that a "second- or third-hand MRI machine" can be purchased by a physician practice or free-standing imaging center for a few hundred thousand dollars but yield millions in new revenue. A report by America's Health Insurance Plans says as many as half the scans are unnecessary, and a McKinsey Global Institute study found the extra machines produce around $26.4 billion in additional costs each year. In addition, they expose patients to avoidable radiation (McNeill, 9/22).
Citing "serious and irreversible harm to teens," the American Civil Liberties Union asked an Illinois court to strike down a newly effective law that prevents teens from having an abortion unless they notify a parent or go to court.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dirk Bradley Bahoravitch, MSN, CRNA 264 N 1020 E, American Fork, UT 84003-2957 Ph: (801) 592-5424 | Dirk Bradley Bahoravitch, MSN, CRNA 1067 N 500 W, Provo, UT 84604-3305 Ph: (801) 374-0354 |
News Archive
GlaxoSmithKline (GSK) and Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (Impax), today announced an agreement for the development and commercialization of IPX066, Impax's novel extended release carbidopa-levodopa product, outside the United States and Taiwan. IPX066, an investigational product under development for the treatment of Parkinson's Disease (PD), is currently in Phase III clinical trials.
The now classic lab manual Antibodies, by Harlow and Lane, has been revised, extended, and updated by Edward Greenfield of the Dana-Farber Cancer Center, with contributions from other leaders in the field.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the bevacizumab (Genentech/Roche/Chugai's Avastin)/paclitaxel (Bristol-Myers Squibb's Taxol, generics)/carboplatin (Bristol-Myers Squibb's Paraplatin, generics) regimen will remain Decision Resources' proprietary clinical gold standard for the treatment of advanced non-small-cell lung cancer through 2018.
The Dallas Morning News reports on the lure of the medical imaging business, which is many say is a "growth industry," including the idea that a "second- or third-hand MRI machine" can be purchased by a physician practice or free-standing imaging center for a few hundred thousand dollars but yield millions in new revenue. A report by America's Health Insurance Plans says as many as half the scans are unnecessary, and a McKinsey Global Institute study found the extra machines produce around $26.4 billion in additional costs each year. In addition, they expose patients to avoidable radiation (McNeill, 9/22).
Citing "serious and irreversible harm to teens," the American Civil Liberties Union asked an Illinois court to strike down a newly effective law that prevents teens from having an abortion unless they notify a parent or go to court.
› Verified 3 days ago
Sarah Ward Barnaby, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-727-2056 Fax: 770-701-6675 | |
Rodney L Fisher, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 320 River Park Dr Ste 125, Provo, UT 84604 Phone: 801-375-8049 Fax: 801-374-9195 | |
Chase Bazil, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1900 N State St Ste 105, Provo, UT 84604 Phone: 801-655-5245 | |
Shelby Lyn Beck, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1067 N 500 W, Provo, UT 84604 Phone: 801-374-0354 | |
Joyce Westphal, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 585 N 500 W, Provo, UT 84601 Phone: 801-375-0983 Fax: 801-375-0988 | |
Samantha Anderson, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 608-695-0168 |